AstraZeneca ' s Imfinzi Prolongs Survival in Aggressive Lung Cancer AstraZeneca ' s Imfinzi Prolongs Survival in Aggressive Lung Cancer

AstraZeneca ' s cancer treatment Imfinzi (durvalumab) has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news